EP14.02-00 Cisplatin in Combination with Entinostat exerts Synergistic Antineoplastic Activity in Small Cell Lung Cancer

A. Schwendenwein, K. Boettiger, I. Kovacs, N. Barany, Z. Megyesfalvi, Michael Grusch, Christian Kowol, M. Rezeli, K. Hoetzenecker, B. Dome, Karin Schelch

Veröffentlichungen: Beitrag in FachzeitschriftMeeting Abstract/Conference PaperPeer Reviewed


Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases and is associated with a poor survival rate. SCLC is a tremendously lethal disease characterized by rapid growth and a high propensity to metastasize. Hitherto, platinum-based chemotherapy is one of the key components of the standard first-line therapeutic regimen of SCLC. Despite the known initial chemosensitivity of SCLC, the prospect of therapeutic success is limited by early relapse and acquired resistance in almost all patients. In recent years, only little progress has been made in the management of the disease although considering the addition of immunotherapy to the therapeutic armamentarium. Entinostat, a class I histone deacetylase inhibitor (HDACi), has been reported to exhibit anti-cancer effects in various human cancers. Entinostat has been demonstrated to synergize with cisplatin and moreover reverses cisplatin resistance. In this study, we investigated the combined effect of cisplatin and entinostat in SCLC with the aim to determine the mechanisms behind differential responses to the combination treatment using proteomic data.
Seiten (von - bis)S537-S537
FachzeitschriftJournal of thoracic oncology
PublikationsstatusVeröffentlicht - Sep. 2022

ÖFOS 2012

  • 302055 Onkologie
  • 104003 Anorganische Chemie
  • 301904 Krebsforschung